Market Overview

Needham Initiates Medtronic At Buy

Related MDT
Is Medtronic (MDT) A Suitable Value Pick Right Now?
Medtronic CRT Devices Improve Therapy Delivery, Cut Costs
Intuitive Surgical Rises As Rivals Fail To Crack DaVinci Code (Investor's Business Daily)

Analysts at Needham initiated coverage on shares of Medtronic (NYSE: MDT) with a Buy rating.

The target price for Medtronic is set to $74.

Medtronic shares have climbed 16.85% over the past 52 weeks, while the S&P 500 index has jumped 16.68% in the same period.

Medtronic's shares fell 1.26% to close at $62.54 yesterday.

Latest Ratings for MDT

May 2017Goldman SachsInitiates Coverage OnNeutral
Jan 2017JP MorganDowngradesOverweightNeutral
Jan 2017Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: NeedhamInitiation Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!